# Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

> **NCT00770133** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 141 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Ketotifen/naphazoline
- **DRUG:** Naphazoline
- **DRUG:** Ketotifen
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00770133
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-04
- **Final completion:** 2010-06
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770133, "Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00770133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*